Sana Biotechnology (SANA) Net Income towards Common Stockholders (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$162.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 25.17% year-over-year to -$162.4 million; the trailing twelve-month figure through Mar 2026 stood at -$534.9 million (down 15.86% YoY), and the FY2025 full-year result was -$369.6 million, down 5.54% from the prior year.
• Net Income towards Common Stockholders retreated to -$162.4 million in Q1 2026, from -$61.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $984000.0 in Q3 2023 to a low of -$493.1 million in Q4 2023.
• A 5-year average of -$161.9 million and a median of -$142.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 101.16% in 2023 and sank 6189.84% in 2024, its largest moves.
• Tracing SANA's Net Income towards Common Stockholders over 5 years: stood at -$83.4 million in 2022, then sank by 491.21% to -$493.1 million in 2023, then surged by 89.38% to -$52.4 million in 2024, then fell by 16.82% to -$61.2 million in 2025, then slumped by 165.42% to -$162.4 million in 2026.
• Business Quant data shows SANA's Net Income towards Common Stockholders at -$162.4 million in Q1 2026, -$61.2 million in Q4 2025, and -$86.1 million in Q3 2025.